Full-length dystrophin reconstitution with adeno-associated viral vectors

Human Gene Therapy

Volumn 25, Issue 6, 2014, Pages 552-562

  Lostal, William ^a,b   Kodippili, Kasun ^a   Yue, Yongping ^a   Duan, Dongsheng ^a  

^a University of Missouri   (United States)

^b Department of Neurology School of Medicine University of Missouri ^*

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRAL VECTOR 2; ADENO ASSOCIATED VIRAL VECTOR 6; ADENO ASSOCIATED VIRAL VECTOR 9; COMPLEMENTARY DNA; DYSTROPHIN; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; DUCHENNE MUSCULAR DYSTROPHY; GENE SEQUENCE; GENETIC ENGINEERING; GENETIC TRANSDUCTION; GENOME ANALYSIS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VIVO GENE TRANSFER; LOW DRUG DOSE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TIBIALIS ANTERIOR MUSCLE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS GENOME; VIRUS RECOMBINATION; WILD TYPE; ANIMAL; BIOSYNTHESIS; DEPENDOPARVOVIRUS; GENE EXPRESSION; GENE THERAPY; GENE VECTOR; GENETICS; MALE; METABOLISM; MOLECULAR CLONING; MUSCULAR DYSTROPHY, DUCHENNE; PROCEDURES; SKELETAL MUSCLE; TUMOR CELL LINE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; CELL LINE, TUMOR; CLONING, MOLECULAR; DEPENDOVIRUS; DYSTROPHIN; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MALE; MICE, INBRED MDX; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; RECOMBINANT PROTEINS; TRANSDUCTION, GENETIC;

EID: 84902983023     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2013.210     Document Type: Article

References (46)

1. Atchison, R.W., Casto, B.C., and Hammon, W.M. (1965). Adenovirus-associated defective virus particles. Science 149, 754-756.
2. Bartoli, M., Poupiot, J., Goyenvalle, A., et al. (2006). Noninvasive monitoring of therapeutic gene transfer in animal models of muscular dystrophies. Gene Ther. 13, 20-28. (Pubitemid 41823848)
3. Bostick, B., Ghosh, A., Yue, Y., et al. (2007). Systemic AAV-9 transduction in mice is influenced by animal age but not by the route of administration. Gene Ther. 14, 1605-1609. (Pubitemid 350056232)
4. Buning, H. (2013). Gene therapy enters the pharma market: the short story of a long journey. EMBO Mol. Med. 5, 1-3.
5. Carter, B.J. (2005). Adeno-associated virus vectors in clinical trials. Hum. Gene Ther. 16, 541-550. (Pubitemid 40740922)
6. Chamberlain, J.S. (1997). Dystrophin levels required for correction of Duchenne muscular dystrophy. Basic Appl. Myol. 7, 251-255.
7. Crawford, G.E., Faulkner, J.A., Crosbie, R.H., et al. (2000). Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain. J. Cell Biol. 150, 1399-1410.
8. Danko, I., Chapman, V., and Wolff, J.A. (1992). The frequency of revertants in mdx mouse genetic models for Duchenne muscular dystrophy. Pediatr. Res. 32, 128-131.
9. Dong, J.Y., Fan, P.D., and Frizzell, R.A. (1996). Quantitative analysis of the packaging capacity of recombinant adenoassociated virus. Hum. Gene Ther. 7, 2101-2112. (Pubitemid 26400735)
10. Dong, B., Nakai, H., and Xiao, W. (2010). Characterization of genome integrity for oversized recombinant AAV vector. Mol. Ther. 18, 87-92.
11. Duan, D. (2011). Duchenne muscular dystrophy gene therapy: lost in translation? Res. Rep. Biol. 2, 31-42.
12. Duan, D., Yue, Y., and Engelhardt, J.F. (2001). Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol. Ther. 4, 383-391.
13. England, S.B., Nicholson, L.V., Johnson, M.A., et al. (1990). Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 343, 180-182.
14. Ghosh, A., Yue, Y., and Duan, D. (2006). Viral serotype and the transgene sequence influence overlapping adeno-associated viral (AAV) vector-mediated gene transfer in skeletal muscle. J. Gene Med. 8, 298-305.
15. Ghosh, A., Yue, Y., Lai, Y., and Duan, D. (2008). A hybrid vector system expands aden-associated viral vector packaging capacity in a transgene independent manner. Mol. Ther. 16, 124-130.
16. Ghosh, A., Yue, Y., and Duan, D. (2011). Efficient transgene reconstitution with hybrid dual AAV vectors carrying the minimized bridging sequence. Hum. Gene Ther. 22, 77-83.
17. Harper, S.Q., Hauser, M.A., Dellorusso, C., et al. (2002). Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med. 8, 253-261.
18. Koenig, M., Beggs, A.H., Moyer, M., et al. (1989). The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am. J. Hum. Genet. 45, 498-506. (Pubitemid 19261437)
19. Koo, T., Malerba, A., Athanasopoulos, T., et al. (2011). Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of alpha1-syntrophin and alpha-dystrobrevin in skeletal muscles of mdx mice. Hum. Gene Ther. 22, 1379-1388.
20. Koo, T., Popplewell, L., Athanasopoulos, T., and Dickson, G. (2014). Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice. Hum. Gene Ther. 25, 98-108.
21. Lai, Y., and Duan, D. (2012). Progress in gene therapy of dystrophic heart disease. Gene Ther. 19, 678-685.
22. Lai, Y., Yue, Y., Liu, M., et al. (2005). Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat. Biotechnol. 23, 1435-1439. (Pubitemid 41679397)
23. Lai, Y., Yue, Y., Liu, M., and Duan, D. (2006). Synthetic intron improves transduction efficiency of trans-splicing adeno-associated viral vectors. Hum. Gene Ther. 17, 1036- 1042. (Pubitemid 46076745)
24. Lai, Y., Thomas, G.D., Yue, Y., et al. (2009). Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J. Clin. Invest. 119, 624-635.
25. Lai, Y., Yue, Y., Bostick, B., and Duan, D. (2010a). Delivering large therapeutic genes for muscle gene therapy. In Muscle Gene Therapy. D. Duan, ed. (Springer Science + Business Media, LLC, New York) pp. 205-218.
26. Lai, Y., Yue, Y., and Duan, D. (2010b). Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb. Mol. Ther. 18, 75-79.
27. Lai, Y., Zhao, J., Yue, Y., and Duan, D. (2013). alpha2 and alpha3 helices of dystrophin R16 and R17 frame a microdomain in the alpha1 helix of dystrophin R17 for neuronal NOS binding. Proc. Natl. Acad. Sci. USA 110, 525-530.
28. Mays, L.E., and Wilson, J.M. (2011). The complex and evolving story of T cell activation to AAV vector-encoded transgene products. Mol. Ther. 19, 16-27.
29. Mingozzi, F., and High, K.A. (2011a). Immune responses to AAV in clinical trials. Curr. Gene Ther. 11, 321-330.
30. Mingozzi, F., and High, K.A. (2011b). Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat. Rev. Genet. 12, 341-355.
31. Odom, G.L., Gregorevic, P., Allen, J.M., and Chamberlain, J.S. (2011). Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6. Mol. Ther. 19, 36-45.
32. Pan, X., Yue, Y., Zhang, K., et al. (2013). Long-term robust myocardial transduction of the dog heart from a peripheral vein by adeno-associated virus serotype-8. Hum. Gene Ther. 24, 584-594.
33. Phelps, S.F., Hauser, M.A., Cole, N.M., et al. (1995). Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum. Mol. Genet. 4, 1251-1258.
34. Qiao, C., Zhang, W., Yuan, Z., et al. (2010). AAV6 capsid tyrosine to phenylalanine mutations improve gene transfer to skeletal muscle. Hum. Gene Ther. 21, 1343-1348.
35. Rumeur, E.L., Hubert, J.F., and Winder, S.J. (2012). A new twist to coiled coil. FEBS Lett. 586, 2717-2722.
36. Shin, J.H., Yue, Y., and Duan, D. (2012). Recombinant adenoassociated viral vector production and purification. Methods Mol. Biol. 798, 267-284.
37. Srivastava, A., Lusby, E.W., and Berns, K.I. (1983). Nucleotide sequence and organization of the adeno-associated virus 2 genome. J. Virol. 45, 555-564. (Pubitemid 13225420)
38. Taghli-Lamallem, O., Jagla, K., Chamberlainc, J.S., and Bodmer, R. (2014). Mechanical and non-mechanical functions of Dystrophin can prevent cardiac abnormalities in Drosophila. Exp. Gerontol. 49, 26-34.
39. Xu, Z., Yue, Y., Lai, Y., et al. (2004). Trans-splicing adenoassociated viral vector-mediated gene therapy is limited by the accumulation of spliced mRNA but not by dual vector coinfection efficiency. Hum. Gene Ther. 15, 896-905. (Pubitemid 39244844)
40. Yue, Y., and Duan, D. (2002). Development of multiple cloning site cis-vectors for recombinant adeno- associated virus production. Biotechniques 33, 672, 674, 676-678.
41. Yue, Y., Li, Z., Harper, S.Q., et al. (2003). Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. Circulation 108, 1626-1632. (Pubitemid 37187791)
42. Yue, Y., Ghosh, A., Long, C., et al. (2008). A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol. Ther. 16, 1944-1952.
43. Yue, Y., Shin, J.-H., and Duan, D. (2011). Whole body skeletal muscle transduction in neonatal dogs with AAV-9. Methods Mol. Biol. 709, 313-329.
44. Zhang, Y., and Duan, D. (2012). Novel mini-dystrophin gene dual adeno-associated virus vectors restore neuronal nitric oxide synthase expression at the sarcolemma. Hum. Gene Ther. 23, 98-103.
45. Zhang, Y., Yue, Y., Li, L., et al. (2013). Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy. Hum. Mol. Genet. 22, 3720-3729.
46. Zhong, L., Li, B., Mah, C.S., et al. (2008). Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl. Acad. Sci. USA 105, 7827-7832. (Pubitemid 351872723)